The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•30 April 2026•

1 min read

Can-Fite Reports Positive Phase 2a Results for Pancreatic Cancer Treatment

Key Facts

1Can-Fite announced positive clinical data from its Phase 2a study of namodenoson in patients with advanced pancreatic cancer.

235% of patients remain on therapy, including one patient who has continued for beyond 16 months.

Can-Fite BioPharma has announced positive clinical data from its Phase 2a study of namodenoson, targeting patients with advanced pancreatic cancer. The trial results revealed that 35% of patients remain on therapy, demonstrating significant treatment durability. Notably, one patient has continued the treatment for over 16 months, highlighting the drug's potential efficacy in a difficult-to-treat population. These findings suggest that namodenoson could offer a viable therapeutic option for patients with limited alternatives. This milestone is critical for the micro-cap biotech firm as it progresses through the clinical trial pipeline. While clinical-stage results carry inherent risks, the sustained response observed in participants provides a bullish outlook for the drug's development.